Automated Enzymatic Assay

The ACE kinetic kit from BÜHLMANN provides ready to use Substrate and highly stable Calibrator and Controls, offering a maximum convenience and accuracy. Reconstituted Calibrator and Controls provided with the kits are stable for 6 months at 2-8°C. Different package sizes are available (2×50, 100, 400 and 1200 tests). Validated application notes are available for most common clinical chemistry analyzers.

Angiotensin Converting Enzyme

In vivo, ACE catalyses the conversion of Angiotensin I to Angiotensin II and inactivates bradykinin during regulating blood pressure via Renin-Angiotensin-System.

Elevated levels of serum ACE have been measured in patients suffering from various disorders. They often indicate a poor prognosis or rapid progression of the disease. Elevated serum ACE levels are reported in granulomatous-inflammatory diseases such as Sarcoidosis and Mixed-Connective-Tissue Disease (MTCD), Nephropathies associated with Diabetes and Glomerulonephritis, Cardiovascular diseases such as left ventricular hypertrophy, brain and myocardial infarction.
The assay aids the assessment of disease activity in patients with sarcoidosis in conjunction with other clinical and laboratory findings.

High Sensitive Methods

In cerebrospinal fluid (CSF) normal ACE activity is far below the detection limit of any commercially available ACE kinetic assay. BÜHLMANN offers a solution to reliably detect even this low ACE activity. The  ACE high sensitive assay (kinetic assay; order code: KK-ACF) with a detection limit of 1 U/L.


BÜHLMANN ACE kinetic – Product Information

Method Enzymatic assay
Time to Result 10 min (approx.)
Sample Type 25 µl serum
Sensitivity 12 ACE units
Order Code KK-ACK  100 tests
KK-ACK2  2×50 tests
KK-ACK4  400 tests
KK-ACKX  1200 tests
CE0123, FDA


Sarcoidosis is an inflammatory disease of unknown origin characterised by the formation of granulomas. The prevalence of this multisystem granulomatous disorder, which activates the immune system, varies between ethnic groups and geographic regions. In about 20% of the cases especially multi-organ involvement may become life-threatening. The chronic forms can last several years or even a life time.

Consequently, diagnostic tools are essential to closely monitor disease activity and to predict disease progression. ACE is valuable to assess the disease activity, especially in systemic Sarcoidosis. It is released by epitheloid cells and its serum level correlates significantly with the granuloma burden of the patient.

The positive predictive value of elevated ACE activity is estimated between 75-90%, the negative predicted value between 70-80%. An initial low ACE activity indicates a good prognosis (Beneteau-Burnat, Baudin, CRC Rev Clin Lab Sci 1991).